Total Payments
$1,232
2024 Payments
$29.96
Companies
8
Transactions
8
Medicare Patients
4,815
Medicare Billing
$1.8M
Payment Breakdown by Category
Consulting$1,000 (81.2%)
Food & Beverage$175.19 (14.2%)
Education$57.04 (4.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,000 | 1 | 81.2% |
| Food and Beverage | $175.19 | 4 | 14.2% |
| Education | $57.04 | 3 | 4.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TESARO, Inc. | $1,000 | 1 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $112.81 | 1 | $0 (2018) |
| CSL Behring | $29.96 | 1 | $0 (2024) |
| Genentech USA, Inc. | $24.73 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $21.50 | 1 | $0 (2018) |
| Novocure Inc. | $16.15 | 1 | $0 (2021) |
| PFIZER INC. | $14.63 | 1 | $0 (2019) |
| Karyopharm Therapeutics Inc. | $12.45 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29.96 | 1 | CSL Behring ($29.96) |
| 2021 | $16.15 | 1 | Novocure Inc. ($16.15) |
| 2020 | $12.45 | 1 | Karyopharm Therapeutics Inc. ($12.45) |
| 2019 | $14.63 | 1 | PFIZER INC. ($14.63) |
| 2018 | $134.31 | 2 | E.R. Squibb & Sons, L.L.C. ($112.81) |
| 2017 | $1,025 | 2 | TESARO, Inc. ($1,000) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/21/2024 | CSL Behring | HEMGENIX (Biological) | Education | In-kind items and services | $29.96 | General |
| Category: Hematology | ||||||
| 06/22/2021 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $16.15 | General |
| Category: Oncology | ||||||
| 11/17/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 02/22/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $14.63 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2018 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $112.81 | General |
| 06/19/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2017 | TESARO, Inc. | VARUBI (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2017 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 956 | 10,097 | $1.0M | $415,030 |
| 2022 | 21 | 1,030 | 17,262 | $1.2M | $494,475 |
| 2021 | 23 | 1,161 | 31,525 | $1.1M | $389,219 |
| 2020 | 32 | 1,668 | 42,505 | $1.6M | $538,218 |
Total Patients
4,815
Total Services
101,389
Medicare Billing
$1.8M
Procedure Codes
105
All Medicare Procedures & Services
105 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 6,600 | $511,000 | $284,174 | 55.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 368 | $117,760 | $36,146 | 30.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 196 | 322 | $69,230 | $20,832 | 30.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 58 | 192 | $101,760 | $20,593 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 67 | 147 | $38,523 | $10,492 | 27.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 75 | $31,875 | $10,068 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 94 | 136 | $25,137 | $6,148 | 24.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 39 | $10,140 | $3,667 | 36.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $11,320 | $3,287 | 29.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 48 | $8,400 | $2,981 | 35.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 15 | 24 | $8,331 | $2,713 | 32.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 39 | 105 | $18,375 | $2,500 | 13.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $8,645 | $2,485 | 28.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 17 | 44 | $11,000 | $2,345 | 21.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $7,275 | $2,085 | 28.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 141 | $12,690 | $1,572 | 12.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 55 | $6,325 | $1,277 | 20.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 30 | 81 | $10,125 | $1,030 | 10.2% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 27 | 670 | $20,100 | $538.85 | 2.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 39 | 996 | $996.00 | $97.34 | 9.8% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 13 | 8,800 | $630,000 | $355,021 | 56.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 174 | 408 | $129,662 | $39,294 | 30.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 232 | 369 | $79,070 | $24,700 | 31.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 54 | 177 | $93,810 | $20,051 | 21.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 62 | 115 | $48,665 | $15,714 | 32.3% |
About Dr. Peter Crow, MD
Dr. Peter Crow, MD is a Hematology & Oncology healthcare provider based in Hooksett, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740233816.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Crow, MD has received a total of $1,232 in payments from pharmaceutical and medical device companies, with $29.96 received in 2024. These payments were reported across 8 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($1,000).
As a Medicare-enrolled provider, Crow has provided services to 4,815 Medicare beneficiaries, totaling 101,389 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 105 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Hooksett, NH
- Active Since 05/18/2006
- Last Updated 02/14/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1740233816
Products in Payments
- VARUBI (Drug) $1,000
- HEMGENIX (Biological) $29.96
- Perjeta (Biological) $24.73
- KEYTRUDA (Biological) $21.50
- Optune (Device) $16.15
- XTANDI (Drug) $14.63
- XPOVIO (Drug) $12.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.